ketorolac has been researched along with Curling Ulcer in 4 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "No subjects treated with parecoxib sodium or placebo developed gastroduodenal ulcers or > or =11 erosions/ulcers." | 5.11 | Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects. ( Harris, SI; Hubbard, RC; LeComte, D; Stoltz, RR, 2004) |
| " In contrast, seven (23%) of the 31 ketorolac subjects had at least one ulcer; five (16%) had gastric ulcers, and two (6%) had duodenal ulcers (p < 0." | 5.10 | Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. ( Dhadda, S; Harris, SI; Hubbard, RC; Kuss, ME; LeComte, D; Stoltz, RR; Talwalker, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harris, SI | 2 |
| Stoltz, RR | 2 |
| LeComte, D | 2 |
| Hubbard, RC | 2 |
| Collen, MJ | 1 |
| Chen, YK | 1 |
| Wolfe, PA | 1 |
| Polhamus, CD | 1 |
| Kubik, C | 1 |
| Robinson, AB | 1 |
| Clement, DJ | 1 |
| Kuss, ME | 1 |
| Talwalker, S | 1 |
| Dhadda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Intravenous Dynastat on Postoperative Sore Throat: A Randomized Double-blinded Controlled Trial[NCT03915561] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | ||
| A Randomized Comparison Between Parecoxib and Placebo Added to a Standard Perioperative Analgesic Protocol for Total Knee Arthroplasty[NCT05924412] | Phase 4 | 40 participants (Anticipated) | Interventional | 2023-07-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ketorolac and Curling Ulcer
| Article | Year |
|---|---|
Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects.
Topics: Adult; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gastrointestinal; | 2004 |
Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects.
Topics: Age Factors; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2002 |
2 other studies available for ketorolac and Curling Ulcer
| Article | Year |
|---|---|
Giant duodenal ulcer and nonsteroidal anti-inflammatory drug use.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; Humans; Ketorolac; Pain, Postop | 1995 |
Giant duodenal ulcers associated with the postoperative use of ketorolac: report of three cases.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Duodenal Ulcer; | 1994 |